Matanis Lobna1, Eiza Nasren1, Sabag Adi1, Bejar Jacob2, Gimenez-Arnau Ana Maria3, Maurer Marcus4, Vadasz Zahava1. 1. The Proteomic and Clinical Flow Cytometry Unit, Bnai-Zion Medical Center, The Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel. 2. Bnai-Zion Medical Center, The Division of Pathology, Haifa 31048, Israel. 3. Department of Dermatology, Hospital del Mar, IMIM, Universitat Autonoma, 08016 Barcelona, Spain. 4. Dermatological Allergology, Allergie-Centrum-Charite, Department of Allergy and Dermatology, Charite-Universitätsmedizin, 12529 Berlin, Germany.
Abstract
Background: Patients with chronic spontaneous urticaria (CSU), an autoimmune disorder, show increased skin expression of IL-17A and can benefit from treatment with the anti-IL-17A biologic secukinumab. The mechanisms that drive IL-17A expression in CSU are currently unknown, but may involve Semaphorin5A (Sema5A). Objective: To explore the expression, role, and effects of Sema5A in CSU and its link to IL-17A. Material and Methods: We investigated patients with CSU and healthy controls for skin expression of expressing peripheral T cells. Results: Sema5A was highly expressed in the skin of CSU patients as compared to healthy control skin. Both CD4+ T cells and mast cells in CSU skin expressed Sema5A, and many of them expressed both Sema5A and IL-17A. Patients with CSU had significantly higher rates of IL-17A-expressing CD4+ T cells as compared to healthy controls. Incubation with Sema5A increased the rates of IL-17A-expressing CD4+ T cells in healthy controls to CSU levels. Conclusion: Sema5A may drive the expression and effects of IL-17A in CSU. Further studies in larger cohorts are needed to confirm the role of Sema5A in the pathogenesis of CSU and to explore its potential as a therapeutic target.
Background: Patients with chronic spontaneous urticaria (CSU), an autoimmune disorder, show increased skin expression of IL-17A and can benefit from treatment with the anti-IL-17A biologic secukinumab. The mechanisms that drive IL-17A expression in CSU are currently unknown, but may involve Semaphorin5A (Sema5A). Objective: To explore the expression, role, and effects of Sema5A in CSU and its link to IL-17A. Material and Methods: We investigated patients with CSU and healthy controls for skin expression of expressing peripheral T cells. Results:Sema5A was highly expressed in the skin of CSU patients as compared to healthy control skin. Both CD4+ T cells and mast cells in CSU skin expressed Sema5A, and many of them expressed both Sema5A and IL-17A. Patients with CSU had significantly higher rates of IL-17A-expressing CD4+ T cells as compared to healthy controls. Incubation with Sema5A increased the rates of IL-17A-expressing CD4+ T cells in healthy controls to CSU levels. Conclusion:Sema5A may drive the expression and effects of IL-17A in CSU. Further studies in larger cohorts are needed to confirm the role of Sema5A in the pathogenesis of CSU and to explore its potential as a therapeutic target.
Entities:
Keywords:
IL-17; T cells; chronic spontaneous urticaria; mast cells; semaphorin5A
Authors: Pavel Kolkhir; Martin K Church; Karsten Weller; Martin Metz; Oliver Schmetzer; Marcus Maurer Journal: J Allergy Clin Immunol Date: 2016-10-21 Impact factor: 10.793
Authors: Stefania Artigiani; Paolo Conrotto; Pietro Fazzari; Giorgio F Gilestro; Davide Barberis; Silvia Giordano; Paolo M Comoglio; Luca Tamagnone Journal: EMBO Rep Date: 2004-06-25 Impact factor: 8.807
Authors: D A Sabag; L Matanes; J Bejar; H Sheffer; A Barzilai; M K Church; E Toubi; M Maurer; Z Vadasz Journal: Clin Exp Allergy Date: 2020-07 Impact factor: 5.018
Authors: Sabine Altrichter; Hans-Jürgen Peter; Dina Pisarevskaja; Martin Metz; Peter Martus; Marcus Maurer Journal: PLoS One Date: 2011-04-12 Impact factor: 3.240